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Abstract
The goal of this literature review was to determine what effects proton pump inhibitors (PPIs)
have on the normal gastrointestinal (GI) flora and how that may lead to weight loss or weight
gain. A literature search was performed using the database PubMed. Only articles from the last
ten years (2009-2019) were included in this review. Keywords used in the search are listed
below. After exclusion criteria was applied, 30 articles were relevant and used in this review.
Five themes were identified in the literature review. An investigation of normal GI flora
associated with weight loss and weight gain identified a common conclusion that the ratio of
Firmicutes to Bacteroidetes was higher in obesity. The investigation of PPIs effects on the
normal GI flora was less conclusive; however, a common finding was an increase in
Streptococcaceae (phylum Firmicutes), which can commonly be found in the oral cavity. This
finding suggests that oral flora may have a greater survival rate in lower parts of the GI system
with treatment of PPIs due to the decreased gastric acidity. The final investigation, which looked
into the association between PPI use and weight change revealed a greater likelihood that PPIs
will cause weight gain with four studies supporting weight gain and two studies supporting
weight loss. Alternative treatments such as H2 receptor antagonists, laparoscopic Roux-en-Y
gastric bypass, probiotics, and lifestyle management were also explored. Although further
research needs to be completed, it appears that PPIs are associated with an increase in
Streptococcaceae of the phylum Firmicutes, which has been linked to weight gain.

Keywords: proton pump inhibitor, PPI, weight, weight gain, weight loss, bacteria, microbiome,
gastrointestinal flora, normal flora, intestinal flora, gut bacteria
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Introduction
Obtaining a patient's BMI, or body mass index, is a routine part of any clinic or hospital
visit. Obesity is a rising crisis in the United States. According to the Centers for Disease Control
(CDC), 39.8% of the US adult population suffers from obesity. That percent does not even
include individuals who are overweight. There is also epidemiological data that shows obesity
and gastroesophageal reflux disease (GERD) are linked. GERD occurs when the lower
esophageal sphincter becomes relaxed and allows gastric acid pass into the esophagus to irritate
the mucosal lining.
One of the first line treatments for those suffering from gastric acid related symptoms are
proton pump inhibitors (PPIs). Proton pump inhibitors decrease gastric acid and therefore relieve
the irritation caused by it. Although lowering gastric acid may increase healing of ulcers and
reduce symptoms of GERD, the stomach's low pH is an important factor in controlling bacteria
within the gastrointestinal system (Ambizas, 2017). Without that control system, bacteria are free
to grow as other factors allow. There have been recent studies showing that different normal
flora are related to an increased ability to lose or gain weight.
The purpose of this study is to explore the effects of PPI use on normal gastrointestinal
flora and how that relates to weight change. This study will also mention alternative treatments
such as H2 antagonists, lifestyle modifications, and surgical intervention.
Statement of the Problem
Weight gain is a significant side effect of some medications and is a strong factor that
influences whether a patient chooses to take a drug or not. This is not only due to aesthetic
reasons, but also risk factors for other diseases. According to the National Institutes of Health
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(NIH), excess weight is linked to greater risk for cardiovascular disease, diabetes, stroke, renal
disease, liver disease, cancer, and many others.
PPIs come with an array of gastrointestinal related side effects. According to U.S.
Pharmacist, PPIs commonly cause nausea, vomiting, diarrhea, and an increased risk of
Clostridium difficile infection. If PPIs have been shown to affect pathogenic bacteria of the
gastrointestinal system like C. difficile, they most certainly influence normal flora as well.
Weight determination is a complex interaction between diet, genetics, physical activity,
medical conditions, and stress. Certain bacteria of the GI system have been found in higher
concentration in overweight individuals compared to those of thin individuals, showing a clear
link between the normal flora of the GI system and weight, making it another factor to consider.
If PPIs do affect the normal flora of the GI system in a way that leads to weight gain, it
will be important to find an alternative treatment of gastric acid related symptoms for those
individuals who are overweight or obese.
Research Question
In patients using PPIs, do the PPI’s effects on normal GI flora lead to weight gain or
weight loss?
Methods
A literature search was performed on PubMed using the following search terms in
various combinations: “proton pump inhibitor,” PPI, weight, “weight gain,” “weight loss,”
bacteria, microbiome, “gastrointestinal flora,” “normal flora,” “intestinal flora,” and “gut
bacteria.” Only articles from the last 10 years were included (2009-2019). Out of 281 total search
results, 38 articles were relevant. Seven were later removed as they were reviews. One study was
also later removed due to the subjects of study being insects, not mammals. All others not
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included in this review lacked relevance because they discussed the effect of PPIs in the
treatment of H. pylori only, or the main topic of the article was not directed at PPIs or weight.
Literature Review
A review of the literature shows that PPIs’ effects on GI flora have been heavily studied;
however, PPIs’ effects on weight has not. The current literature that is available demonstrates
many conflicting results on whether PPIs cause weight gain, weight loss, or no change in weight.
Although there are conflicting results regarding PPIs and weight, there is solid evidence
regarding PPIs’ effects on GI flora and which flora are associated with weight gain and weight
loss.
Normal GI Flora Associated with Weight Gain
The ratio of Firmicutes to Bacteroidetes was higher in obesity (Hou et al., 2017).
Enterococcus, Blautia, Sutterella, Klebsiella, and Collinsella were also increased in obesity. Hou
and colleagues obtained these results through investigating the differences in gut microbiota in
obese and healthy children. 87 obese children and 56 healthy children age 3-18 had fecal DNA
samples analyzed. None of these children had antibiotics in the three months prior to the study.
The researchers looked at the 16S rRNA gene, the enterotypes, and quantity of the gut
microbiota. They also analyzed the fecal samples of the obese children during weight reduction.
Unfortunately, this study lacked information about the time frame of fecal collection and
demographics of the children, as well as their health history. Although the study failed to record
some information, results showed significant differences between gut microbiota in obese
children and healthy children (principal coordinate analysis, P <0.01). It also showed that the
amount of Bifidobacterium and Lactobacillus increased during weight reduction (Wilcoxon’s
rank sum test, P <0.01). There was also a higher ratio of Firmicutes to Bacteroidetes in obese
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children, as well as an enrichment of Enterococcus, Blautia, Sutterella, Klebsiella, and
Collinsella. According to another study referenced in the Hou study, Collinsella has been found
to positively correlate with insulin and is enriched in type 2 diabetes suggesting a relationship
with insulin resistance in obese individuals. In healthy children, Bacteroides, Parabacteroides,
Anaerotruncus, and Coprobacillus were enriched.
Menni et al. (2017) showed conflicting results to that of Hou et al. (2017). Menni showed
that Bacteroides is associated with increased risk of weight gain and that Firmicutes (part of
Ruminococcaceae) is associated with lower long-term weight gain. Ruminococcaceae and
Lachnospiraceae were associated with lower long-term weight gain (OR=0.89 (0.05), P=0.038)
via logistic regressions. Although Bacteroides was associated with increased risk of weight gain,
the correlation seemed to be driven by the lower levels of diversity. A low gut microbiome
diversity appears to be associated with greater weight gain over time. Gut microbiota diversity
was negatively associated with long-term weight gain via random intercept logistic regressions
(P <0.05). The gut microbiota diversity was also positively correlated with fiber intake
(Shannon: beta (s.e.)= 0.01 (0.004), P=0.002) and negatively associated with risk of being in the
high weight gain group (OR (s.e.)= 0.977 (0.96-0.99), P= 0.017) via linear regressions. It is
unclear if the low bacterial diversity is a cause or consequence of weight gain. The goal of this
study was to determine if there was a correlation between change in body weight over time and
gut microbiome composition. Not only did this study accomplish its goal, it also determined that
weight gain relies more heavily on environmental factors than heritability. Less than half of the
variation in long-term weight change was found to be heritable (h2=0.41 (CI: 0.31, 0.47)). To
obtain the results discussed above, 1632 Caucasian, female twins from the TwinsUK registry had
fecal samples collected. 16S ribosomal RNA gene sequence data (composition of gut
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microbiome) was analyzed as well as BMI (average 9.09 years apart with SD 3.45), calorie
intake (via food frequency questionnaires), and physical activity (using a Likert scale). The
strength of this study is the number of factors considered: age, sex, smoking, calorie intake,
physical activity, family relatedness, and BMI. The limitations of this study were that diet and
physical activity information was drawn from questionnaires and not an observed program. The
study also only analyzed women, therefore failing to consider sex differences. Finally, the study
lacked measures of microbiome composition at baseline.
The study performed by Muniz Pedrogo et al. agreed with Hou’s results, Dialister
(phylum Firmicutes) was increased in those with reduced weight loss (Muniz Pedrogo et al.,
2018). Dialister is associated with oral infections. If Dialister is able to make it to the intestinal
tract, possibly via gastric acid suppression with PPIs, it could explain an association between
PPIs and weight gain. The goal of this study was to determine if compositional and functional
characteristics of the gut microbiota in adults predicted responses to a comprehensive lifestyle
intervention program in overweight and obese adults. To investigate their goal, 26 adults age 1865 with a BMI of 27-39.9 from the Mayo Clinic Obesity Treatment Research Program were
recruited between August to September 2013 to participate in a lifestyle intervention program for
weight loss. The mean age of all participants was 53.5 years (95% CI: 50.3 – 56.8) with 81% of
participants being female. None of the participants had health problems that prevented them from
physical activity or a history of previous surgeries for weight loss. They also were not currently
in another weight loss program and had not taken weight loss medications or antibiotics in the
previous 30 days. The participants were also not allowed to take probiotics. The participants
were required to get 10,000 steps per day (monitored by a 7-day pedometer) and increase the
amount of fruits, vegetables, and low energy density food intake while lower foods with greater
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nutrient density. They met weekly for the first 3 months and used the outline of the Look
AHEAD protocol to guide their meetings. At baseline and at 3 months, data was collected: age,
sex, race, weight, height, BMI, smoking status, hypertension, pre-diabetes, type 2 diabetes,
fasting blood glucose, HDL levels, LDL levels, triglycerides, and stool samples. Success was
defined as 5% or greater weight loss. Stool samples were analyzed based on 16S rRNA. Twosided Wilcoxon rank-sum tests were used to compare baseline differences in bacterial
composition and alpha diversity. It was also used for interval changes in bacterial composition
and diversity between baseline and three months. Permanova was used for beta diversity. The
results showed Phascolarctobacterium was significantly increased at baseline in subjects that
lost at least a 5% weight loss after 3 months (LDA 2.09, P=.008) and Dialister was significantly
increased in those with less than 5% weight loss (LDA −2.07, P=.03). There was no change in
the gut microbial composition and diversity after 3 months. The strengths of this study were the
close observation of the participants and the many metabolic factors they take into account at
baseline and at 3 months. However, the study was limited by its small sample size and the short
time frame.
A study performed by Stark, Susi, Emerick, and Nylund notes that Actinobacter (higher
in obese), Bacteroidetes (lower in obese), and Firmicutes (increased in obese) have been found
to be increased in PPI users (Stark, Susi, Emerick, & Nylund, 2019). They also found that PPIs
have a greater influence on weight than either H2RAs or antibiotics. This information was
discovered while investigating the association of antibiotic, histamine-2 receptor antagonist, and
proton pump inhibitor prescriptions in children diagnosed with obesity. To study this association,
a retrospective cohort study of 333,353 children born into the US Military Health System
between October 2006 and September 2013 was performed. To be included in the study, they
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had to have a set of vital signs with height and weight recorded between October 2008 and
September 2015 and be eligible for TRICARE. They excluded infants who were low birth
weight, premature, or had an initial hospital stay greater than seven days. An exposure was
considered a prescription for an antibiotic, H2RA, or PPI in the first two years of life. Obesity
was defined by the US CDC as a BMI greater than or equal to the 95th percentile for age and sex.
A single event analysis of obesity was performed using Cox proportional hazards regression
starting at age two because the CDC growth charts are recommended starting at age two. An
ordinal variable was created for acid suppressing medications representing 30-day intervals.
Antibiotics were divided into subgroups of one, two, three, or greater than three antibiotic class
exposures. A similar subgrouping was made for those exposed to one, two, three, or none of the
medications groups in the study. The results showed that of the 333,353 children, 11.8% were
prescribed H2Ras, 3.3% were prescribed PPIs, and 72.4% were prescribed antibiotics. 14.1%
developed obesity with the median age (P25-P75) for the first reading being 3.03 (2.27-4.07).
11% of the children who developed obesity were not exposed to any of the medications. For PPI
prescriptions, the percent of obesity was greater than either H2RAs or antibiotics (16.6%
compared to 15.1% and 15.3% respectively). For PPI prescriptions, the incidence density of
obesity was 3.85, the unadjusted HR (95% CI) was 1.04 (1.03-1.05), and the adjusted HR (95%
CI) was 1.02 (1.01-1.03). The strengths of this study are the large and diverse population, and the
standardized measurements such as the CDC growth chart. The limitations of this study include
the lack of information regarding if the patient actually took the medication prescribed, as this
study only took into account prescriptions that were filled. Medications could have also been
purchased or obtained outside of TRICARE such as in the ER or urgent care setting. It is also
unknown what the mother’s health habits were and how well the children were fed.
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A study by Ward et al. agrees with three of the four studies above. PPI use before and
after the surgery was correlated with an increase in Firmicutes and a decrease in Bacteroidetes
(Ward et al., 2014). PPI use also was associated with decreased weight loss. This information
supports other articles in that low Bacteroidetes and high Firmicutes is considered an obese
profile and that PPIs may be responsible for the shift in microbiota. The goal of this study was to
assess the association between PPI use and the gut microbiota prior to laparoscopic Roux-en-Y
gastric bypass (LRYGB) and at six months post-LRYGB and the relationship of post-LYRGB
PPI use with weight loss. Eight severely obese adult patients (BMI >40) at the Ohio State
Wexner Medical Center who were candidates for LRYGB were recruited for this study between
December 2010 and December 2011. Their weight had to be stable one month before surgery,
and they could not be taking antibiotics, probiotics, steroids, or other immunosuppressant
medications 30 days before providing a stool sample. Data collected were weight, height, and
PPI use as defined by the use of a PPI for four or more per week for the prior month. Nonusers
must not have taken a single dose of a PPI or H2 blocker in the two weeks before stool collection
and they must not have been a regular PPI or H2 blocker user at any time during the previous
three months. Fecal samples provided were self-collected and stored at -80oC until analysis. Only
5/8 patients provided the six-month sample. The fecal samples were analyzed using 16S rRNA
genes. Mean percent relative abundances (PRA) were compared between PPI users and PPI
nonusers using an unpaired Student’s t test. Weight loss was defined by percent weight loss
(PWL) and percent excess weight loss (PEWL), which were both calculated. The results
showed the mean PRA of Firmicutes was higher in PPI users (71.6%, 48.6%) than in non-PPI
users (52.1%, 35.6%) (before and after LRYGB respectively). The mean PRA of Bacteroidetes
was lower in PPI users (5.4%, 5.9%) than in non-PPI users (15.8%, 22.6%) (before and after
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LRYGB respectively). The PRA of Proteobacteria was lower in PPI users (6.8%) than non-PPI
users (19.5%) before LRYGB; however, after the results were similar (13.8% compared to
12.4%). Escherichia of Proteobacteria was higher in PPI users both before (4.5% vs. 0.4%) and
after (10.8% vs. 3.7%). The PRA of Akkermansia of Verrucomicrobia was higher in PPI users
(12.8%) than non-PPI users (7.2%) before LRYGB; however, after Akkermansia increased in
both groups (28% and 26.3% respectively). Patients using PPIs had poorer weight loss than nonPPI users (PWL of 27.4 ± 4.6 % compared to 31.1 ± 8.0 %, and PEWL of 49.3 ± 9.0 % compared
to 61.4 ± 2.0 %). The major limitation of this study was its small sample size.
Normal GI Flora Associated with Weight Loss
Akkermansia muciniphila is associated with a better metabolic profile or weight loss (Dao
et al., 2016). The goal of this study was to evaluate the association between Akkermansia
muciniphila abundance, fecal microbiome gene richness, diet, host characteristics, and their
changes after calorie restriction. A. muciniphila is a bacterial species inversely associated with
body fat mass and glucose intolerance in mice. This human study involved 49 overweight and
obese adults in Paris, France that were enrolled in a 6-week calorie restriction followed by 6
weeks of a weight stabilization diet. Anthropometric measurements, subcutaneous white adipose
tissue samples, 7-day dietary records, fecal samples, and blood samples were taken at baseline,
week 6, and week 12. The results showed that individuals with higher abundance of Akkermansia
had a lower waist-to-hip ratio (0.96 (0.01) for low and 0.92 (0.02) for high, p value 0.04), lower
leptin (44.1 ng/ml (3.6) for low and 30.9 ng/ml (3.9) for high, p value 0.005), lower fasting blood
glucose (5.4 mmol/L (0.1) for low and 5.2 mmol/L (0.1) for high, p value 0.02), and lower
insulin (11.3 ulU/ml (0.9) for low and 8.9 ulU/ml (0.9) for high, p value 0.03). These results
suggest a better metabolic profile for those with higher abundance of Akkermansia. The strength
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of this study was the many metabolic parameters being measured. The limitation of this study
was that they did not a have a control (healthy) population. Also, of the 49 participants 41 were
female, which does not provide a good sample size for gender differences.
As discussed in Normal GI Flora Associated with Weight Gain, Hou’s goal was to
investigate the differences in gut microbiota in obese and healthy children to develop further
understanding of the mechanism of obesity development (Hou et al., 2017). The study found that
Bacteroides, Parabacteroides, Anaerotruncus, and Coprobacillus were enriched in healthy
children, suggesting these bacteria may be correlated with weight loss. It also showed that the
amount of Bifidobacterium and Lactobacillus increased during weight reduction (Wilcoxon’s
rank sum test, P <0.01). There was also a higher ratio of Firmicutes to Bacteroidetes in obese
children compared to healthy children. Therefore, the bacteria associated with a lower weight
are: Bacteroides, Parabacteroides, Anaerotruncus, Coprobacillus, Bifidobacterium, and
Lactobacillus.
Another study, like Ward et al. (2014), investigated the association of bariatric surgeries
and changes to the GI microbiome. According to Ilhan et al. (2017), Gammaproteobacteria,
Prevotellaceae, and Bacilli may be associated with greater weight loss. The goal of the study
was to determine differences in the microbiota after Roux-en-Y gastric bypass and laparoscopic
adjustable gastric banding surgeries and reveal links between microbiome and weight loss
associated products after bariatric surgeries. The study notes that the higher gastric pH in RYGB
patients allows for greater microbial diversity because it increases the chance of survival of acidsensitive microorganisms. Between 2011 and 2014, researchers recruited four different groups of
people from Mayo Clinic, AZ: patients who had RYGB (24) or LAGB (14) surgeries, healthy
normal weight (10), and morbidly obese controls who were scheduled to undergo bariatric
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surgery (15). Patients were to not use prebiotics/probiotics and preferably no PPIs two weeks
before fecal collection. They were also not allowed to be on antibiotics within two months of
fecal collection. The surgical group had to have had their surgery at least 9 months before
testing. Participants also provided a 4-day food diary and food frequency questionnaire 2 weeks
before stool sampling. DNA analysis was performed on the stool using 16S rRNA gene data. The
results showed that percent excess weight loss was significantly higher for the RYGB group than
the LAGB group (P<0.05). When analyzing the microbiomes, they did not cluster based on BMI,
diet composition, sex, or age (permutational analysis of variance P>0.05). This meant that
RYGB surgery was the main factor for the change in the gut microbiota. Gammaproteobacteria
and Prevotellaceae were found more in RYGB than in nonsurgical patients.
Gammaproteobacteria and Bacilli were elevated in RYGB compared to LAGB. They also found
that RYGB had higher microbial diversity than LAGB or pre-surgical patients (P<0.05). Low
diversity has been associated with obesity. This study’s strength was its focus on long term
changes to the gastrointestinal microbiome, however, many of the results were statistically
insignificant.
Mailhe et al. showed that the change in gastrointestinal pH due to PPI use changes the
microbiota diversity (Mailhe et al., 2018). Patients using PPIs had greater bacterial diversity
(p<0.001). In other studies, the higher diversity is associated with weight loss. The goal of this
study was to analyze the human microbiota from the upper to the lower GI tract using
culturomics and metagenomics. One strength of this study is the sampling from multiple areas of
the GI system. Unlike most studies that have just taken stool samples, this study also obtained
samples from the upper GI system. There were six patients who underwent a colonoscopy and
endoscopy simultaneously with gastrointestinal content sampled in five different locations along
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the GI tract. These samples were analyzed via MALDI-TOF and 16S rRNA gene amplification
and sequencing. This was another strength of this study- using two different methods to analyze
the bacteria. A comparison of the human microbiota of patients treated with PPIs to those who
were not revealed that PPI use raised stomach and duodenal pH (untreated stomach and
duodenum vs treated: 1.8 and 2.5 vs. 7.0 and 7.1 [p<0.001]). In untreated individuals, they
isolated 754 species with 377 being aerotolerant. In treated individuals, they isolated 960 species
with 462 being aerotolerant. The limitations of this study were its small sample size, the lack of
information regarding how long the patients were on PPIs, and the lack of information on other
parameters of the patients they sampled from such as: BMI, diet, exercise, gender, and age.
Muniz Pedrogo et al. (2018), as discussed in the theme Normal GI Flora Associated with
Weight Gain, not only found that Dialister was associated with increased weight, the study also
found that Phascolarctobacterium was increased in those with increased weight loss.
Phascolarctobacterium was significantly increased at baseline in subjects that lost at least a 5%
weight loss after three months (LDA 2.09, P=.008).
A study by Nadal et al. (2009), showed an increase in Bacteroides is related to weight
loss, which supports other articles’ results. It also showed that reductions in C. histolyticum and
proportions of E. rectale to C. coccoides correlated with decreased weight. The group that didn’t
experience significant weight loss also didn’t experience any significant change to their
microbiota, which suggests microbial change is directly related to weight change. The goal of
this study was to evaluate the effects of a weight loss program on the fecal microbiome of
overweight and obese adolescents and how that relates to weight loss. This was a longitudinal
intervention study in Spain on 39 teenagers (ages 13-16) who had BMIs that ranged from 23.750.4. There were 20 females and 19 males. They were placed on calorie restriction (10-40%) and
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increased their physical activity (determined by accelerometry) for 10 weeks. They were also
provided counseling to educate them on diet, give them techniques to help change behaviors, and
provide general support. They kept food diaries for 72 hours before the study and 72 hours at the
end of the study to determine average intake of energy. Blood work was taken to determine their
lipids, glucose, and fasting plasma insulin levels. Fecal samples were also taken at baseline and
at 10 weeks. Fluorescent in situ hybridization followed by flow cytometry was used to determine
the bacterial groups present in the feces. Feces were also dried into duplicate 1.5 g samples and
their energy content was determined by the Automatic Adiabatic Bomb Calorimeter. The results
showed that 26 of the 39 had significant weight loss with a mean of 7.6 kg (P= 0.050). Thirteen
of the 39 did not have significant weight loss with a mean decrease of 1.1 kg (P=0.798). Both
groups had a significant decrease in caloric intake (P<0.050). They found reductions in
Clostridium histolyticum correlated with weight loss (r=0.43; P=0.009) and BMI z-scores
(r=0.41; P=0.012). Reductions in proportions of E. rectale to C. coccoides also correlated with
weight loss (r=0.50; P=0.001) and BMI z-scores (r=0.39; P=0.014).They also found a significant
increase in Bacteroides (P=0.047) which almost reached correlation with weight loss (r=-0.28;
P=0.083). Although there were other shifts in bacterial groups, they were not significantly
correlated with weight loss or with BMI z-scores. In the group that didn’t experience significant
weight loss, there was no significant shift in bacterial groups or correlations with bacteria to
body weight or BMI z-scores. There were no conflicts of interest. The limitations of this study
are the small sample size and the lack of control over the type of food eaten and the type of
exercise performed.
The study by Sanmiguel et al. (2017) not only suggests various bacteria that may be
responsible for weight loss, but also the way they contribute to weight loss. For example,
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Enterococcus is associated with lower appetite and Akkermansia is associated with reduced
hedonic eating. This study also agreed with many others regarding a decrease in the Firmicutes
to Bacteroides ratio being related to weight loss. The goal of this study was to determine if
laparoscopic sleeve gastrectomy causes changes to the gastrointestinal microbiota and whether
those changes are related to weight loss. Eight obese adult women (BMI= 44.1 [5.6]) at the
UCLA Ronald Reagan Medical Center who were to undergo laparoscopic sleeve gastrectomy
(LSG) were recruited between June 2014 and June 2015. They measured height, weight, BMI,
waist circumference, percent body fat, lean body mass, dietary intake, hunger and satiety ratings,
and Yale Food Addiction Scale scores at baseline and at one month post-surgery. Stool samples
were also analyzed at baseline and at one month post-surgery using 16S rRNA gene sequencing.
Diversity analysis was performed on the stool samples for alpha diversity (within a sample) and
beta diversity (across samples). Differences in taxonomic abundance of the gastrointestinal
microbiome pre- and post LSG were also evaluated. The results showed that LSG was associated
with a significant increase in Fusobacteria (log2FC= 4.0, q=4.1E-07) and a significant decrease
in Firmicutes/Bacteroidetes ratio (p=0.008) due to a decrease in Firmicutes (log2FC= -0.71,
q=0.0055). After surgery Bifidobacteriacceae decreased (log2FC= -8.4, q=0.0003), and
Fusobacterium (log2FC= 4.3, q= 0.0005), Atopobium (log2FC= 4.1, q=0.01), and Bulleidia
(log2FC= 3.8, q= 0.04) increased. “Several bacterial genera were significantly associated with
weight loss (Bilophila, q = 3E-05; Faecalibacterium q = 4E-05), lower appetite (Enterococcus, q
= 3E-05), and reduced hedonic eating (Akkermansia, q = .037) after surgery” (Sanmiguel et al.,
2017). The strength of this study lies in its statistical analysis. The limitation of this study is the
small sample size in a short timeframe. This study also involved a questionnaire, in which it is
possible that the women did not truthfully report their hedonic eating.
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Shin et al. (2016) found that PPI use is associated with weight loss. It also disagreed with
other studies, showing Firmicutes was the predominant bacterial phylum associated with weight
loss/PPI use. The goal of this study was to assess changes in gastrointestinal microbiota of rats
treated long-term with a proton pump inhibitor, lansoprazole. There were eleven 24-week-old
male Fischer rats used in this study. For 50 weeks, five rats were fed Purina rat chow and six rats
were fed the same feed with lansoprazole (5 mg/kg/day). To make the medicated chow, one
gram of lansoprazole was mixed with 20 kg of rat chow. The average rat body weight was
presumed to be 400 g and daily chow intake was presumed to be 40 g. After the 50 weeks, the
rats were anesthetized, killed, and stripped of a 1-cm length of their terminal ileum. The lumen
of the terminal ileum was flushed with phosphate buffered saline and the flushed material was
formed into pellets via centrifugation. Barcoded pyrosequencing of the 16S rRNA gene was
performed on the microbial DNA extracted from the pellets. The results showed that “rats treated
with lansoprazole showed significantly reduced body weight compared to controls (322.3±15.3 g
vs 403.2±5.2 g, p<0.001).” The microbiota of the control rats showed 93.9% Proteobacteria
(increased Escherichia and Pasteurella). The microbiota of the PPI treated rats showed 66.9%
Firmicutes (Clostridium or Lactobacillus). There was no statistical significance in the diversity
of the microbiota within the control and treated groups. The strength of this study was its length.
The limitations of this study were the small sample size, the lack of control of food intake, and
that they only examined the microbiota of the terminal ileum. Because the rats were fed ad
libitum, the daily dose of PPI could not be determined and therefore the change in weight may be
due to differences in food intake. This study was also performed on rats, meaning that their
results may not translate to human studies.
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Proton Pump Inhibitors’ Effects on Normal GI Flora
Streptococcaceae increases in the gut after PPI therapy (Bajaj et al., 2014).
Streptococcaceae is abundant in the oral cavity, but it is usually destroyed by gastric acid. PPIs
increase of gastric pH may be contributing to the survival of Streptococcaceae in the intestinal
tract. The goal of this study was to assess the changes in gut microbiota composition and
function in patients with cirrhosis and without after a two week course of omeprazole. Fifteen
patients with cirrhosis without decompensation and 15 healthy age-matched controls who had
not been on PPIs were recruited for the study. At baseline and at two weeks, patients had blood
gastrin levels drawn, a 24 hour food recall was done, their MELD score determined, and fecal
and urine samples collected. For two weeks, patients were given 40 mg of omeprazole at
breakfast while maintaining their dietary pattern. Microbial DNA was analyzed using Length
Heterogeneity PCR fingerprinting of 16S rRNA, Multitag Pyrosequencing, and the Bayesian
analysis tool in RDP10. The results showed >95% adherence to omeprazole as demonstrated by
pill bottle return. There was no significant change in MELD score (P=0.5), the controls’ caloric
intake (P=0.4), or the cirrhosis patients’ caloric intake (P=0.6). There was a significant increase
in Streptococcaceae after omeprazole therapy in both cirrhosis patients (baseline 0.0 vs. 8.9%, P
= 0.0008, FDR = 0.008) and controls (baseline 0.2 vs. 5.7%, P = 0.0009, FDR = 0.007). The
strengths of this study are there are no conflicts of interest in this study and they also agematched their controls. The limitations of this study are its small sample size and short study
period.
Another study found a relationship between PPI use and Streptococcaceae. Haemophilus
and Streptococcus increase with PPI therapy, and Lactobacillus and Stenotrophomonas decrease
with PPI therapy (Castellani et al., 2017). The goal of this study was to determine how PPIs
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affect the microbiome of infants with gastroesophageal reflux disease. This was a prospective
longitudinal interventional study. Twelve infants (8 males, 4 females) with proven GERD under
the age of one were enrolled in this study between November 2014 and August 2016. Stool
samples were collected before initiation of esomeprazole therapy (1 mg/kg body weight oral),
after four weeks of therapy, and at four weeks post PPI therapy. Patients received the PPI for a
variable amount of time (8-44 weeks) depending on their symptoms. They didn’t receive any
antibiotics or other acid suppressant, and their diets were recorded. Microbial DNA was
extracted from the stool samples and analyzed using 16S rRNA gene data. The results showed
that alpha (Chao1 index, p=0.729) and beta (unweighted UniFrac, p=0.913) diversity of the
microbial populations did not change after treatment with PPIs. However, after the PPI was
discontinued, the third sample showed increased alpha (p=0.003) and beta (p=0.003) diversity.
PPI therapy caused a significant increase in Haemophilus, and a significant decrease in
Lactobacillus and Stenotrophomonas. Streptococcus was also increased, although not
significantly. The strengths of this study were that GERD was proven in the infants by 24-hour
pH impedance monitoring. All of the patients’ GERD resolved, suggesting appropriate acid
suppression. There were also no conflicts of interest. The limitations of this study were the small
sample size and the variable lengths of time patients were exposed to esomeprazole. This study
also lacked a control group (one that was not exposed to PPI therapy).
PPI use decreases the abundance of Bacteroidetes and increases the abundance of
Firmicutes (Clooney et al., 2016). This is an important finding because the other studies have
found that increased Firmicutes was associated with an obese profile. In this study, the bacteria
that increased within Firmicutes were Holdemania, Streptococcus, and Blautia. The goal of this
study was “to compare the fecal microbiomes of long-term PPI users to those with no history of

EFFECT OF PPIS ON GI FLORA LEADING TO WEIGHT CHANGE

22

PPI use” (Clooney et al., 2016). Sixty-one participants were enrolled in this cross-sectional
study, 32 PPI users and 29 controls. All participants were found using the Manitoba Health
Population Health Registry. The PPIs users had to be age 50 or over and been dispensed over
180 PPI tablets in five years prior to the study. The controls had to be age 50 or older and not
been dispensed any PPIs in the five years prior to the study. All participants gave data regarding
current or prior PPI use, the type of PPI, the dose, the indication for PPI use, gastrointestinal
symptoms, and other medications used. All participants also completed a Food Frequency
Questionnaire. The participants then collected a stool sample at home and were told to store it in
a refrigerator until shipment to the study center in Manitoba. The stool samples were then frozen
and shipped to Ireland for microbial DNA analysis using 16S rRNA gene data. The results
showed that “the abundance of Bacteroidetes was lower in PPI users relative to the non-PPI
control group (P < 0.007), while the abundance of Firmicutes was higher (P < 0.008).” Within
Firmicutes, three genera were significantly increased: Holdemania (P<0.0003), Streptococcus
(P<0.036), and Blautia (P <0.077). The two most commonly used PPIs were omeprazole and
rabeprazole. The strengths of this study were the larger sample size and the long term use of
PPIs. The limitations of this study were that they did not survey participants on their antibiotic
usage, they could not determine if there was a change from the baseline gut microbiome in PPI
users as this was a cross-sectional study, and they could not determine if the effects would be the
same with short-term PPI use.
Freedberg et al. agreed with Castellani et al. and Bajaj et al., PPI use increases
Enterococcaceae and Streptococcaceae (Freedberg et al., 2015).The goal of this study was to
determine if PPIs alter the gut microbiome to increase the risk of Clostridium difficile infection.
The study was an open-label, randomized crossover trial that involved 12 healthy participants
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age 18 or older who had not used antibiotics, PPIs, or H2 antagonists within one year, had not
used new medications within one month, did not have chronic GI mucosal disease or abnormal
bowel frequency, did not use medications that interact with PPIs, were not pregnant, and did not
have travel plans outside the US during the study period. Fecal samples were taken at week zero
and week four of which they were not on any PPIs. The participants were then randomized into
groups of four weeks vs eight weeks of PPI treatment with 40 mg of omeprazole twice daily.
After four weeks of treatment, they all donated another fecal sample. After eight weeks of
treatment, the final fecal samples were collected. Fecal microbiomes were determined using 16S
rRNA gene sequencing. The results showed that microbial diversity did not change after four
weeks or 8 weeks of PPI treatment. After four weeks of PPI therapy, Enterococcaceae and
Streptococcaceae increased. Enterococcaceae has been associated with C. diff infections in other
studies, and Streptococcaceae is predominantly an upper GI microbe that has been associated
with small intestinal bacterial overgrowth in other studies. They also found a 44% median
decrease in Clostridiaceae (P= 0.03). No further changes were seen in participants on the eight
week trial of PPIs. The strengths of this study were in its exclusion criteria of participants and the
randomization of four vs eight week PPI groups. The limitations of this study were its focus on
bacteria that have already been associated with C. difficile infection, as well as its small sample
size.
In the study by Gommers et al. (2019), PPIs induce a change in the gastrointestinal
microbiome including: a decrease in diversity, an increase in Lactobacillus, and an increase in
Bifidobacterium. The goal of this study was to examine how PPIs and magnesium intake affect
the gut microbiome. Forty-eight male mice were randomly placed into four experimental groups.
Two groups were fed low magnesium (0.05%) diets and two groups were fed normal magnesium
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(0.22%) diets. Omeprazole 20 mg/kg body weight was then given for four weeks to a group from
each diet and the other two groups were given a placebo. The mice were weighed daily. At
baseline, two weeks, and after four weeks of treatment, urine and feces were collected and their
food and water intake was determined. After the treatment was completed, the mice were
anesthetized and killed. Their stomach pH was measured using diagnostic test strips. The fecal
microbiome was determined via extraction of DNA followed by 16S rRNA gene analysis. The
results showed that omeprazole decreased the microbial diversity compared with the controls
(P=0.027) independent of magnesium intake. In omeprazole treated mice, Lactobacillus
increased 3-fold compared to the placebo treated mice, and Bifidobacterium increased 2-fold
compared to the placebo treated mice. These genera rose independently of magnesium
differences. The strength of this study was that the mice were placed in a controlled
environment. The limitation of this study was that the test subjects were mice and therefore these
results may not transfer to human studies.
According to Hojo et al. (2018), PPIs increase the abundance of facultative anaerobes in
the GI tract: Lactobacillus, Streptococcus, Enterobacteriaceae, and Staphylococcus. The goal of
this study was to examine the fecal microbiota composition after PPI use. This observational
study examined 20 patients (13 males, 7 females) who were at least 20 years old and had
confirmed grade A or greater reflux esophagitis. They were recruited between October 2014 and
September 2016 from Juntendo University Hospital Department of Gastroenterology. Exclusions
included: PPI use or antibiotic use within one month of the study, living probiotic or yogurt
within one month of the study, a history of GI resection, and patients with upper GI ulcers or
malignancies. Eight weeks of either esomeprazole (20 mg), rabeprazole (10 mg), or lansoprazole
(30 mg) were given once daily. Fecal samples were collected for DNA analysis by 16S and 23S
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rRNA targeted quantitative RT-PCR at baseline, at four weeks of treatment, and at eight weeks
of treatment with PPIs. They also measured fecal pH with an IQ 150 pH Thermometer. The
results showed Lactobacillus, a facultative anaerobe, significantly increased between baseline
and four weeks (P= 0.011), as well as baseline and eight weeks (P= 0.002). Streptococcus,
another facultative anaerobe genus, significantly increased between baseline and four weeks (P=
0.005) and baseline and eight weeks (P < 0.0001). Enterobacteriaceae and Staphylococcus, two
more facultative anaerobes, significantly increased between baseline and eight weeks (P= 0.003
and P= 0.002, respectively). The strength of this study is its use of two methods of DNA
detection (16S and 23S rRNA). The limitations of this study are its small sample size and the
short duration of the study. They were not able to determine if gastrointestinal microbiome
changes with PPI use stayed following discontinuation of the PPIs. They also did not use the
same PPI or dose between patients.
Imhann et al. (2016) found that PPI use is correlated with an increase in facultative
anaerobes such as Enterococcus and Streptococcus, which was in agreement with Hojo et al.
Enterococcus, Streptococcus and Veillonella can all be found in the oral cavity. Some of the
bacterial changes were increases in oral bacteria in the gut, supporting the idea that PPI use
decreases stomach acid, therefore allowing oral bacteria to survive into the gut. The study also
found PPI use correlated with increased BMI. The goal of this study was to determine how PPIs
affect the gut microbiome. A total of 1815 adults from the Netherlands were recruited from three
different cohorts: 1174 individuals from a general population study LifeLines-DEEP (Cohort 1),
300 inflammatory bowel disease patients from the University Medical Center Groningen (Cohort
2), and 189 irritable bowel syndrome patients and 152 matched controls from Maastricht
University Medical Center (Cohort 3). The patients’ medications and PPI use was recorded for
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all three cohorts with Cohort 1 and 3 self-reporting via a standardized questionnaire, and Cohort
2 information coming from electronic medical records. Age, gender, and BMI of all patients was
recorded. Cohorts 1 and 2 collected stool samples at home and immediately froze their samples
in their home freezer to be collected by a research nurse at a later date. Cohort 3 provided a stool
sample within 24 hours of production to the research facility where it was then frozen. One
hundred sixteen healthy volunteers also gave oral cavity mucus samples via buccal swab.
Bacterial DNA analysis was performed using sequencing of the 16S rRNA gene. The results
showed that 211 of the 1815 individuals used PPIs and generally had higher BMIs compared to
non-users: 26.9 (SD 5.0) and 24.9 (SD 4.2), (p=1.89*10-8, WMW test). Firmicutes was the most
abundant phylum in all cohorts. PPI use in all three cohorts resulted in a moderate decrease in
alpha diversity (Shannon index p=0.01, species richness p=0.02). 92 of 460 bacterial taxa
significantly increased or decreased in PPI users compared to non-users (FDR<0.05). Some
increases include Bacilli (Lactobacillales, Staphylococcaceae, Bacillales),
Gammaproteobacteria (Pasteurellaceae, Enterobacteriaceae), Actinomycetales
(Streptococcoceae, Micrococcoceae), and Veillonella. Some decreases include
Bifidobacteriaceae, Ruminococcaceae, and Tenericutes. In PPI users, the gut microbiome shifted
towards bacteria found in the oral samples compared with non-users (p= 1.39*10-20, Wilcoxon
test). Stool frequency and consistency was not related to PPI use in Cohort 1. The strengths of
this study are its large sample size and comparison of gut bacteria to oral bacteria. It also used
meta-analysis to compare the three cohorts. The limitations of this study are inconsistent stool
sampling methods between the cohorts and the many factors needing to be accounted for such as
bowel disease, other medication use, differing diets and exercise, and different duration and dose
of PPI treatment- of which many of these factors were not studied.
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Jackson et al. (2016) is in agreement with the previous two studies regarding the increase
in oral flora within the GI tract after PPI use. This study showed an increase in
oral/mouth/nose/skin bacteria in the gut with PPI use, which supports the survival of these
bacteria past the decreased stomach acidity. Bacteroidales, Rothia, and Streptococcus increased
while Firmicutes decreased with PPI use. There was also lower diversity with PPI use. The goal
of this study was to evaluate the relationship between PPI use and the gut microbiome. One
thousand eight hundred twenty-seven healthy, elderly twins (90% female) from TwinsUK had
PPI data, fecal samples, food frequency questionnaire data, and height and weight measurements
taken. Fecal samples were analyzed using 16S rRNA profiling. Forty-nine percent had selfreported a GI indication for PPIs, 12% had been prescribed PPIs, and 39% had no PPI
prescriptions or GI indications. The results showed PPI users had higher BMIs (p=0.002) and
had significantly lower microbial diversity (p<0.05) compared to non-users. Firmicutes phylum
was significantly lower in PPI users. Bacteroidales family, Rothia genus (q<10-5, B=0.51), and
Streptococcus genus (q<10-6, B=0.47) were significantly increased in PPI users. Using data from
the human microbiome project, the researchers were able to assign bacterial families to their
body site preference. It was found that six of the 10 families positively associated with PPI use
showed site preference for the mouth or throat, a significant positive correlation (p=0.38,
p=0.0019). One of the 10 families showed site preference for the skin or nose, a significant
positive correlation (p=0.36, p=0.003). Along with most increased families associated with PPI
use showing site preference outside of the gut, gut site preference bacteria were decreased with
PPI use. The strengths of this study are the large sample size and the use of twins. The
limitations of this study are that 90% of the population is female and PPI use was not controlled
(timing, dose, brand).
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Bacilli, Lactobacillus, Streptococcaceae, and Veillonella increased with PPI use, as
Enterobacteriaceae was negatively associated with PPI use (Koo et al., 2018). Although PPI use
changed the gut microbiome, this study also showed that the gut does have the ability to reverse
the changes with cessation of treatment if treatment is short term. The goal of this study was to
determine how PPI use, ethnicity, and gender impact the gut microbiome. Thirty-four healthy
individuals of Asian ethnicity of the age range 21-37 years old were enrolled in this study in
Singapore. The three Asian ethnicities were Chinese (n=12, 50% male), Malay (n=12, 50%
male), and Indian (n=10, 40% male). They all provided a baseline stool sample, then took
omeprazole 20 mg daily for seven days, provided a second stool sample at day seven, and then
provided the final stool sample seven days after cessation of treatment at day 14. Throughout the
study, they were required to keep a log of any side effects or diarrhea. After stool collection, the
samples were frozen and sent to the laboratory within four hours. Microbial DNA analysis was
performed using the 16S rRNA gene. The results showed that after seven days of treatment,
species richness (p=0.018) and alpha diversity (p=0.14) increased but then reverted to baseline
by day 14. There was no diversity difference between ethnicities or gender. There was also no
difference in beta diversity. At seven days of treatment, there was a significant increase in Bacilli
class (p=0.0001), Lactobacillus order (p=0.0001), Streptococcaceae family (0=0.0001), and
genera Streptococcus (p=0.0001) and Viellonella (p=0.0041). These results all returned to
baseline by day 14. Enterobacteriaceae family decreased with PPI use. The strengths of this
study are the consistent use of PPIs and the balance of gender distribution. The limitations of this
study are small sample size and the short timeframe.
Streptococcus increased as a result of PPI use according to Mishiro et al. (2018). This
study also found that PPI use affects not only the gut, but also the oral cavity. The goal of this
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study was to determine the effects of PPIs on oral and gut microbiota. Ten healthy adults (eight
male, two female) had fecal, saliva, and periodontal pocket fluid samples taken at baseline and
after four weeks of treatment with esomeprazole 20 mg daily. The participants were 100%
compliant with treatment and reported no gastrointestinal symptoms before or after treatment
with the PPI. The microbiome DNA of each sample was analyzed using 16S rRNA sequences.
The results showed alpha diversity was significantly different between the three sampling
locations, but not between PPI use and no PPI use. There were no changes seen in the phyla
before and after PPI usage, but changes were seen at the genus level. Streptococcus significantly
increased in fecal samples with PPI use (P=0.044, q<0.05). All other fecal microbiota remained
stable before and after PPI usage, but Fusobacterium and Leptotrichia increased in periodontal
pocket fluid (P= 0.030, q= NS; P=0.002, q<0.05), and Neisseria and Veillonella decreased in
saliva (P=0.034, q<0.05; P=0.008, q<0.05). The strengths of this study are there are no conflicts
of interest and that they analyzed samples from mouth to colon. The limitation of this study was
the small sample size.
Streptococcaceae is increased compared to Prevotellaceae in PPI users, which were
results opposite that of the controls (Parsons et al., 2017). It also showed that the ratio of
Firmicutes to Bacteroidetes increased in PPI users. Actinobacillus and Tannerella decreased with
PPI use. The goal of this study was to determine the gastric mucosal microbiota profiles in
patients with hypochlorhydria induced by H. pylori induced atrophic gastritis, autoimmune
atrophic gastritis, and PPI use. Twenty normal adults and 19 PPI treated adults were included in
this study involving a total of 95 participants. All study individuals underwent gastric corpus
biopsies. From these samples, microbial DNA was analyzed via 16S rRNA sequencing. The
results showed PPI treated patients had slightly more Firmicutes and fewer Bacteroidetes than
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normal stomachs. Normal stomachs had significantly more alpha diversity than any other group.
The most abundant bacterial family in PPI users was Streptococcaceae (17%) followed by
Prevotellaceae (11%), as normal stomachs had opposite results with Prevotellaceae (23%) being
the most abundant followed by Streptococcaceae (10%). Genera Actinobacillus and Tannerella
were decreased in PPI users. The strength of this study was the sampling method, taking
biopsies. The limitations of this study were the small sample size and lack of data regarding PPI
use and diets.
PPI use reduces microbial diversity (Seto, Jeraldo, Orenstein, Chia, & DiBaise, 2014).
The goal of this study was to examine how PPI use (short- and long-term) affects the fecal
microbiome and how the changes compare with newly diagnosed C. Difficile infections. Ten
healthy adults from Mayo Clinic in Arizona were split into two groups: five received 20 mg of
omeprazole once daily for 28 days, and five received 20 mg of omeprazole twice daily for 28
days. Their BMIs were recorded and stool samples were collected at baseline, seven days of
treatment, 28 days of treatment, and at one month after treatment cessation. Fecal microbiota
DNA analysis was performed using 16S rRNA gene data. The data collected was then compared
to fecal DNA data from five PPI treatment-naïve C. Difficile infection patients. The results
showed decreased bacterial species count from baseline to one month of PPI use (50,000 to
25,000 reads/sample). There was no difference in operational taxonomic unit counts between
high and low dose PPI use at each stool sampling time points (p= 0.2778, p=0.2063, p=0.5556,
p=0.2778). The strengths of this study were the length of the study and the controlled use of
PPIs. The limitations of this study were its small sample size and its lack of investigation into the
upper gastrointestinal tract.
Shi et al. (2019) showed that PPI use altered both the gastric mucosal microbiota and the
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fecal microbiota. Planococcaceae, Oxalobacteraceae, and Sphingomondaceae were elevated in
gastric mucosal samples, and fecal samples of PPI users showed significantly higher abundances
of Streptococcaceae, Veillonellaceae, Acidaminococcaceae, Micrococcaceae, and
Flavobacteriaceae. The goal of this study was to investigate the association between changes in
gastric mucosal and fecal microbiota and PPI use. From June 2013 to July 2014, 40 Chinese
gastroesophageal reflux (GERD) patients and 15 healthy controls were enrolled in this study.
Healthy controls had a normal clinical exam as well as no use of PPIs at least 30 days before the
study. GERD patients were confirmed to have esophagitis via endoscopy. PPI use was broken
into two categories: short-term (at least two months but less than one year) and long-term (at
least one year), All patients provided fecal samples, and five healthy controls, 10 non-PPI-users,
and 20 PPI users provided gastric mucosal samples. Microbial DNA analysis was performed
using 16S rRNA gene data. The results showed no significant alpha diversity differences in the
gastric mucosal samples between healthy controls and PPI-users. Alpha diversity differences
between fecal samples in PPI use compared to non-PPI use was not significantly different. PPI
users had higher abundances of Planococcaceae, Oxalobacteraceae, and Sphingomondaceae in
gastric mucosal samples. Fecal samples of PPI users showed significantly higher abundances of
Streptococcaceae, Veillonellaceae, Acidaminococcaceae, Micrococcaceae, and
Flavobacteriaceae. Ruminococcus was lower in the short-term PPI use group compared to nonusers and long-term users, as Streptococcus was higher in short-term users compared to nonusers. The strengths of this study were no conflicts of interest and sampling from the upper and
lower gastrointestinal system. The limitations of this study were the small sample size and the
possible contamination of gastric mucosal samples with gastric fluid.
Shin et al. (2016) found that Firmicutes was the predominant bacterial phylum associated
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with weight loss/PPI use, as discussed in Normal GI Flora Associated with Weight Loss. The
microbiota of the PPI treated rats showed 66.9% Firmicutes (Clostridium or Lactobacillus) as
compared to the control rats, which showed 93.9% Proteobacteria (increased Escherichia and
Pasteurella). There was no statistical significance in the diversity of the microbiota within the
control and treated groups. Lansoprazole was the PPI used in this study on rats.
Sterbini et al. (2016) showed that PPI use increased gastric Firmicutes, specifically
Streptococcaceae. Genera that decreased with PPI use were Tannerella, Enhydrobacter, and
Mogibacterium. The goal of this study was to determine the effect PPIs have on gastric mucosal
associated microbiota in patients with dyspepsia. This study was unlike the other because it
demonstrated the bacterial changes occurring in the gastric mucosa as opposed to stool samples.
Twenty-four adults who underwent upper gastrointestinal endoscopy for dyspepsia in Rome,
Italy at the Agostino Gemelli Hospital were included in this study. Twelve patients were
currently on 40 mg daily of omeprazole and twelve patients were either PPI naïve or had stopped
PPI treatment at least six months before the study. Exclusion criteria were: PPI users less than 12
months, antibiotics sooner than three months before the study, history of peptic ulcer disease,
history of gastric surgery, chronic NSAID use, or use of any other acid reducing drugs (H2
antagonists, antacids). After a 12-hour fast, patients underwent upper GI endoscopy to have
biopsies taken from the stomach antrum. Bacterial DNA was analyzed using 16S rRNA gene
pyrosequencing. The results showed that PPI use and H. pylori status did not influence species
richness (Chao1, ANOVA, P>0.05). The relative abundance of Firmicutes was higher in PPI
users than non-users (FDR-adjusted Q=0.047). Streptococcaceae (phylum Firmicutes) were
significantly more abundant in PPI users (FDR-adjusted Q=0.0001). The genera that decreased
with PPI use were Tannerella (Bacteroidetes, P=0.009), Enhydrobacter (Proteobacteria,
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P=0.043), and Mogibacterium (Firmicutes, P=0.040). The strengths of this study were the use of
a consistent dose and brand of PPI and the technique for which samples were collected. The
limitations of this study were the lack of information regarding microbiota changes lower in the
gastrointestinal system and the small sample size.
Takagi et al. (2018) showed there was change in beta diversity but not alpha diversity in
PPI users. It also showed that Firmicutes and Bacteroidetes phyla did not change with PPI use
which is in disagreement with many of the other articles. Interestingly, it revealed a significant
increase mostly in Streptococcus and a significant decrease mostly in Faecalibacterium. The
goal of this study was to determine how long-term PPI use affects the microbiome of Japanese
individuals. From November 2016 to November 2017, 72 Japanese patients from an outpatient
clinic were recruited to participate in this study. Half were PPI users consisting of PPI treatment
at least one year prior to the study. The PPIs used were esomeprazole, lansoprazole, rabeprazole,
and omeprazole. The other half of study individuals were age and sex-matched controls that had
not used PPIs at least five years prior to the study. Fecal samples were collected and stored for
seven days at a temperature no greater than room temperature. DNA sequencing was performed
using the 16S rRNA gene, followed by microbiome analysis. The results showed significant beta
diversity between PPI users and non-users (unweighted p<0.02, weighted p<0.01), but no
significant difference in alpha diversity. The abundance of Firmicutes and Bacteroidetes in PPI
users compared to non-users showed no significant difference. The abundance of Proteobacteria
and Actinobacteria was higher in PPI users than non-users but the results were not statistically
significant. Eight genera were significantly decreased in PPI users: Faecalibacterium, SMB53,
and Clostridium (p<0.01); Turicibacter, Slackia, Defluviitalea, Dehalobacteriaceae, and
Oribacterium (p<0.05). Five genera were significantly increased in PPI users: Streptococcus
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(p<0.01); Ruminococcus, Megasphaera, Actinomyces, and Granulicatella (p<0.05). The strength
of this study was the age and sex-matched controls. The limitations of this study were the small
sample size, the various PPIs used for varying durations, and the fecal samples not being chilled.
Two of the authors also received funding from pharmaceutical companies, which represents a
conflict of interest.
Ward et al. (2014) found that PPI use before and after laparoscopic Roux-en-Y gastric
bypass (LRYGB) was correlated with an increase in Firmicutes and a decrease in Bacteroidetes.
It also found that PPI use was associated with decreased weight loss. This information supports
other articles in that low Bacteroidetes and high Firmicutes is considered an obese profile and
that PPIs may be responsible for the shift in microbiota. Other bacteria that were affected by PPI
use were Escherichia and Akkermansia. Both Escherichia and Akkermansia were increased with
PPI use, however, Akkermansia increased in non-PPI users after LRYGB as well. Refer back to
Ward under Normal GI Flora Associated with Weight Gain for the complete data.
Yamamoto et al. (2019) found that the abundance of Firmicutes was less in PPI users
than non-users, and the abundance of Bacteroidetes was greater in PPI users than non-users. This
study also listed various genera affected by PPIs: Lactobacillus, Streptococcus, Selenomonas,
Veillonella, Campylobacter, and Haemophilus were all abundant in the PPI group. The goal of
this study was to investigate the changes PPIs cause to gut microbiota in Japanese patients with
chronic liver disease. They were also interested in the relationship between PPI use and hepatic
encephalopathy and spontaneous bacterial peritonitis. Sixty-two age, sex, and Child-TurcottePugh score-matched Japanese patients from the NAGOYA gut microbiota database were
included in the study. 31 were PPI users for at least one year before stool collection and 31 had
not used PPIs at least one year prior to stool collection. PPIs used included: esomeprazole (20
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mg daily), rabeprazole (10 mg daily), lansoprazole (15 mg daily), and vonoprazan (20 mg daily).
Stool samples were collected at the beginning of the study, and every 3-6 months after stool
collection, liver function tests were obtained. Stool samples were collected either in the hospital
or in their homes, and then analyzed via 16S rRNA gene sequencing. The results showed
Firmicutes was higher in the non-PPI group (36.7% vs. 31.9%) and Bacteroidetes was higher in
the PPI group (58.4% vs. 50.7%). The strength of this study was groups are age, sex, and ChildTurcotte-Pugh score-matched. The limitations of this study were the small sample size and its
use of only fecal samples, which may not account for small intestine bacteria or mucosal
bacteria.
Proton Pump Inhibitors’ Effects on Weight
PPI use was associated with obesity and an increased weight gain in the study by
Czwornog and Austin (2015). There is still some question as to if the weight gain is due to a
slightly higher fat intake or due to decreased muscle strengthening exercise. The goal of this
study was to examine if there are differences in energy intake, diet composition, and physical
activity between PPI users and nonusers. They also investigated whether PPI use was associated
with change in body weight. This was a cross-sectional study using information from the
National Health and Nutrition Examination Survey. They examined 3073 adults age 20-74
between 2005 and 2006. Exclusion criteria were BMI < 18.5, pregnant, individuals who
answered that they were on a diet. Surveys were conducted in person, online, and via
questionnaires. They collected data on medication use, two 24-h dietary recalls, physical activity
and sedentary behaviors in the previous 30 days, self-reported weight change over the past year,
and basic demographics. Multivariable regression analyses (adjusted for covariates) were
performed to determine the relationship between PPI use and the other survey data. The results
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showed “PPI users had a higher BMI (p < 0.001) and were more likely to be obese (45.4% vs.
30.6%; p = 0.008).” People who took PPIs consumed a similar number of calories compared to
non-PPI users (p= 0.95). PPI users did consume a higher proportion of fat in their diet (34.5% vs.
33.2%; p=0.02). Their intake of carbohydrates, protein, and alcohol was similar to non-PPI users.
PPI users reported similar frequencies of walking, biking, moderate/vigorous activity, computer
use, and TV use. The only activity that PPI users engaged in less was muscle-strengthening
activities (OR: 0.53; 95% CI: 0.30-0.95). Women self-reported more weight gain in one year
compared to men. Men who were PPI users gained 1.52 ± 0.6 kg more than non-PPI users (p=
0.021). Women who used PPIs gained 0.39 ± 1.0 kg compared to women who did not use PPIs
(p=0.71). The strength of this study was the large sample size. The limitation of this study was
its subjective nature. All data in the study is self-reported meaning that people could be falsifying
information or underreporting.
Hsien-Hao, Harn-Shen, and Chih-Yen (2015) present an alternative answer to most of the
studies included in this literature review. It states that PPIs do not have an effect on weight. The
goal of this study was to evaluate whether PPI use is related to weight gain in adults older than
40 years of age. 25 patients who had a normal BMI and H. pylori gastric ulcer proven by upper
endoscopy were recruited for this study. All patients were treated for H. pylori with rabeprazole
20 mg twice daily, as well as clarithromycin 500 mg twice daily and amoxicillin 1000 mg twice
daily for seven days. After antibiotic treatment was complete, patients continued rabeprazole 20
mg once daily for four months. After four months, BMI and body weight were obtained as well
as upper endoscopy to confirm H. pylori eradication. The results showed there was no significant
change in body weight or BMI associated with PPI use or H. pylori eradication. Nineteen of the
25 patients had eradicated H. pylori. The strength of this study was the consistent treatment
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between all study individuals. The limitation of this study was its small sample size and lack of
information regarding diet. Antibiotics were also used in this study which are known to affect
gastrointestinal flora, and therefore may impact weight.
As discussed in Normal GI Flora Associated with Weight Loss, Mailhe et al. (2018)
shows that the change in gastrointestinal pH due to PPIs changes the microbiota diversity.
Patients using PPIs had greater bacterial diversity (p<0.001). In other studies, the higher diversity
is associated with weight loss.
PPI use is associated with weight loss in the study by Shin et al. (2016). The results
showed that “rats treated with lansoprazole showed significantly reduced body weight compared
to controls (322.3±15.3 g vs 403.2±5.2 g, p<0.001).” It also showed Firmicutes was the
predominant bacterial phylum associated with weight loss/PPI use as discussed under Normal GI
Flora Associated with Weight Loss. This study disagreed with many other studies which found
that increased Bacteroides, not Firmicutes, was associated with weight loss. However, this study
was performed on rats and therefore may not translate to human studies.
As discussed in Normal GI Flora Associated with Weight Gain, Stark et al. (2019) found
that PPIs have a greater influence on weight than either H2RAs or antibiotics. The goal of this
study was to investigate the association of antibiotic, histamine-2 receptor antagonist, and proton
pump inhibitor prescriptions during early childhood with a diagnosis of obesity. An exposure
was considered a prescription for an antibiotic, H2RA, or PPI in the first 2 years of life. Obesity
was defined by the US CDC as a BMI greater than or equal to the 95th percentile for age and
sex. Of the 333,353 children, 11.8% were prescribed H2Ras, 3.3% were prescribed PPIs, and
72.4% were prescribed antibiotics. Fourteen point one percent developed obesity with the
median age (P25-P75) for the first reading being 3.03 (2.27-4.07). Eleven percent of the children
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who developed obesity were not exposed to any of the medications. For PPI prescriptions, the
percent of obesity was greater than either H2RAs or antibiotics (16.6% compared to 15.1% and
15.3% respectively). For PPI prescriptions, the incidence density of obesity was 3.85, the
unadjusted HR (95% CI) was 1.04 (1.03-1.05), and the adjusted HR (95% CI) was 1.02 (1.011.03). We must also remember that this study lacked information regarding if the patient actually
took the medication prescribed, as this study only considered prescriptions that were filled.
Medications could have also been purchased or obtained outside of TRICARE such as in the ER
or urgent care setting.
PPI use was associated with decreased weight loss according to Ward et al. (2014).
Patients using PPIs had poorer weight loss than non-PPI users (percent weight loss of 27.4 ± 4.6
% compared to 31.1 ± 8.0 %, and percent excess weight loss of 49.3 ± 9.0 % compared to
61.4 ± 2.0 %). This could be due to the finding of increased Firmicutes and a decrease in
Bacteroidetes, which is associated with an obese profile in other studies. Refer back to Ward
under Normal GI Flora Associated with Weight Gain for the complete data.
PPI use was correlated with weight gain in the study by Yoshikawa, Nagato, Yamasaki,
Kume, and Otsuki (2009). The goal of this study was to examine how PPI use affects weight and
BMI in patients being treated for GERD. 52 patients with GERD and 58 age- and sex- matched
controls in Japan were selected between June and November of 2005. The patients with GERD
were treated with PPIs between 0.8 and 5.7 years and were also advised on lifestyle
modifications such as avoiding overeating, decrease fat intake, elevate the head of their bed, stop
smoking, avoid laying down after eating for at least three hours, and body weight control. The
controls did not have reflux symptoms, were not using PPIs or H2 antagonists, and had annual
follow up visits. The controls did not receive lifestyle modification advice. The PPIs used were
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omeprazole (20 mg), rabeprazole (20 mg), or lansoprazole (30 mg) once daily for eight weeks
followed by a daily half-dose maintenance therapy. Every four weeks the GERD patients were
monitored for their symptoms and either taken off of the PPI or placed back on it. At baseline
(four weeks before the start of the study) and at the end of treatment, GERD patients and the
controls had weight, height, blood pressure, fasting total protein, total cholesterol, and
triglycerides measured. The results showed a significant weight gain (P < 0.0001) and increased
BMI (P < 0.0005) between baseline and their last visit in patients who were treated with PPIs.
There was no significant change in weight or BMI in the control group. Ninety-one percent of
the control groups weight remained stable compared to only 60% of the PPI group. Thirty-six
percent of the PPI treated group gained greater than 5% of their baseline weight as compared to
only 4% of the control group (P < 0.0001). The strengths of this study were the large sample size
and the similarities between the treatment group and the control group in regard to
demographics. The limitations of this study were the lack of control of time of PPI treatment, the
type and dose of PPI, and the lack of information regarding adherence to lifestyle modifications.
Alternative Treatments and the Effects on GI Flora or Weight
The study by Hou et al. (2017), discussed in previous sections, not only showed various
bacteria associated with obesity and with healthy weight in children, it also shows that dietary
change as a method of weight reduction can influence the gastrointestinal microbiota. It showed
that the amount of Bifidobacterium and Lactobacillus increased during weight reduction
(Wilcoxon’s rank sum test, P <0.01). Both of these bacteria are commonly found in probiotics.
Ilhan et al. (2017) shows that RYGB is the best surgical method for weight loss. The
results showed that percent excess weight loss was significantly higher for the RYGB group than
the LAGB group (P<0.05). This can be explained by the higher gastric pH in RYGB patients,
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which allows for greater microbial diversity because it increases the chance of survival of acidsensitive microorganisms. Greater microbial diversity in other studies has been associated with a
decreased risk of obesity. This study found that RYGB had higher microbial diversity than
LAGB or pre-surgical patients (P<0.05).
H2RAs may be an alternative solution to decreasing gastric acid that have less of an
effect on weight than PPIs. This is supported by the results found in Stark et al. (2019). Stark et
al. found that PPIs have a greater influence on weight than either H2RAs or antibiotics. For PPI
prescriptions, the percent of obesity was greater than either H2RAs or antibiotics (16.6%
compared to 15.1% and 15.3% respectively). As discussed in previous sections, the goal of this
study was to investigate the association of antibiotic, histamine-2 receptor antagonist, and proton
pump inhibitor prescriptions during early childhood with a diagnosis of obesity.
As discussed in the prior theme, PPI use was correlated with weight gain in the study by
Yoshikawa et al. (2009). This study also offered alternative solutions to treating GERD. Lifestyle
management may be not only an addition to PPI therapy, but also an alternative to PPI therapy.
Lifestyle modifications include dietary changes, sleep position modifications, smoking cessation,
and weight control. Patients with GERD in this study were advised on lifestyle modifications
such as avoiding overeating, decreasing fat intake, elevating the head of their bed, stop smoking,
avoid laying down after eating for at least three hours, and body weight control.
Discussion
Proton pump inhibitors (PPIs) are a first line treatment for patients who have conditions
related to over production of gastric acid such as gastroesophageal reflux disease (GERD) and
peptic ulcer disease (PUD). According to Mayo Clinic, obesity puts patients at a greater risk for
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developing GERD; therefore, it is important that the medications a patient takes to treat GERD
will not cause further weight gain.
PPIs work by irreversibly binding to the hydrogen potassium adenosine triphosphatase
enzyme (proton pump) in the parietal cells of the stomach (Ambizas & Etzel, 2017). This
binding suppresses acid production, which raises the pH of the stomach. Stomach acid is known
to be a protective mechanism against pathogens trying to colonize lower parts of the
gastrointestinal tract (Ambizas & Etzel, 2017). If the acidity is suppressed, microorganisms from
the oral cavity and from the food we eat are able to survive into the lower parts of the GI tract.
One of the microorganisms found to be increased in the lower parts of the GI tract after PPI use
is Streptococcaceae. Of the studies investigating PPIs effects on normal GI flora, 14 of 18 found
that Streptococcaceae was increased with PPI use. Streptococcaceae is abundant in the oral
cavity, but it is usually destroyed by gastric acid (Bajaj et al., 2014). The suppression of gastric
acid by PPIs appears to allow Streptococcaceae to survive past the stomach.
Streptococcaceae belongs to the phylum Firmicutes. Firmicutes is found to be associated
with an obese profile according to four of the five studies investigating normal GI flora
associated with weight gain. Combining these results, we see that the use of PPIs increases
Streptococcaceae of Firmicutes, which is associated with an obese profile or weight gain, and
therefore it appears that PPI use may lead to weight gain. This result is supported by four of the
seven studies investigating PPIs effect on weight. Of the three studies that did not support weight
gain with PPI use, one found PPIs had no effect on weight and two found PPI use was correlated
with weight loss. Mailhe et al. found that the weight loss was due to the greater microbial
diversity with PPI use. Shin et al. found PPI use was associated with weight loss in a study
conducted on rats. The four studies correlating with weight gain were performed on humans.
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By combining the results found in this literature review, it appears that PPI use is more
likely to lead to weight gain than weight loss. Alternative treatment options may be preferred for
people who are struggling with obesity. Some of those treatment options may include H2
antagonists, lifestyle modifications, or surgical intervention. Another option may be utilizing
probiotics with PPIs to balance the effects on GI flora. Although further research needs to be
performed on probiotic use, some bacteria that may be useful in weight loss are Akkermansia and
Bacteroides. Lactobacillus is a common bacterium used in current probiotics, but it is unclear if
Lactobacillus is associated with weight loss or weight gain as there are conflicting results in the
studies included in this literature review.
In conclusion, PPI use appears to increase Streptococcaceae of Firmicutes, leading to
weight gain. People who are overweight should consider alternative or combined treatments.
Applicability to Clinical Practice
With the information provided in this literature review, providers will be able to choose
whether PPIs are right for their patients suffering from conditions related to elevated gastric acid.
They will be able to accurately disclose to their patients how weight is affected with PPI use. By
knowing how PPIs affect weight, patients will be able to make lifestyle modifications should
they choose to continue using PPIs. Patients may also choose alternative treatments such as H2
receptor antagonists. With further research, probiotics may prove beneficial in conjunction with
PPIs.
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